Clinical Trial Update: T-Cell Responses to Neoantigens Post Treatment With Ipilimumab in Men With Metastatic Castration-Resistant Prostate Cancer [EARLY_Phase 1]

View source ↗

Summary

This document reports an early-phase trial evaluating T-cell responses to neoantigens after treatment with ipilimumab in men with metastatic castration-resistan…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• Ipilimumab (Yervoy) (ipilimumab)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Prostate Cancer | EARLY_Phase 1 | Status: COMPLETED